Werner Engl
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Journal: Expert review of hematology
Published: August 30, 2023
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study.
Journal: Therapeutic advances in hematology
Published: October 13, 2022
Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
Journal: Journal of thrombosis and haemostasis : JTH
Published: October 03, 2022
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.
Journal: Immunotherapy
Published: December 21, 2021
Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: February 15, 2021
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Journal: Journal of clinical immunology
Published: September 24, 2020
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 03, 2020
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
Journal: Thrombosis and haemostasis
Published: May 06, 2020
Assessing goodness-of-fit for evaluation of dose-proportionality.
Journal: Pharmaceutical statistics
Published: March 04, 2020
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: December 20, 2019
Last Updated: 09/26/2026